source
- FDA urges biosimilar makers to adopt alternatives to clinical efficacy trialsFDA's Office of Therapeutic Biologics and Biosimilars, led by director Sarah Yim, announced that the agency is working to help sponsors rely less on clinical efficacy studies when developing biosim…
- Sanofi halts development of Nurix's STAT6 degrader programSanofi announced it will stop work on an experimental drug that targets STAT6, a protein involved in immune signaling. The compound, known as SAR448272 and developed in partnership with Nurix, was…